Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MART-1 Dendritic Cell Vaccine in Melanoma
NCT00039325Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2002
- Primary completion
- Sep 2005
- Modality
- Gene Editing, Whole Cell Cancer Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label trial of mart-1 adenovirus-transduced dendritic cells in Malignant Melanoma (MM) (5 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Optimal dose of vaccine therapy at 7 months. Started Mar 2002; status: completed.
02
Drugs
mart-1 adenovirus-transduced dendritic cells
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00039325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039325.